Compare ONL & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | CNTX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5M | 116.7M |
| IPO Year | N/A | 2021 |
| Metric | ONL | CNTX |
|---|---|---|
| Price | $2.26 | $1.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 308.1K | ★ 680.8K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,775,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $0.49 |
| 52 Week High | $4.25 | $1.55 |
| Indicator | ONL | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 49.78 |
| Support Level | $1.97 | $1.08 |
| Resistance Level | $2.28 | $1.34 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 93.06 | 35.90 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.